Melanoma, Melanoma Stage III
Conditions
Keywords
CD8+ Cell Imaging, C-IT Neo Trial, stage III melanoma, 89Zr-Df-Crefmirlimab, Memorial Sloan Kettering Cancer Center, 21-456
Brief summary
Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the cancer and prevent recurrence after surgery. Treatment given before surgery is called neoadjuvant therapy. The purpose of this study is to find out whether neoadjuvant therapy with nivolumab and ipilimumab can kill melanoma tumors before surgery and prevent disease from coming back after surgery. This study also explores a new, experimental PET scan that images the immune system to see if it is related to treatment outcomes.
Interventions
DIAGNOSTIC_TESTPET Scan
Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab 1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma.
DRUGNivolumab
Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab 1mg/kg + ipilimumab 3mg/kg.
DRUGIpilimumab
Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab 1mg/kg + ipilimumab 3mg/kg.
PROCEDURESurgical Resection of Melanoma
Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab 1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is capable of understanding and complying with the protocol requirements and has signed the Informed Consent document. * Adults at least 18 years of age * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Cytologically or histologically confirmed stage IIIB, IIIC, IIID, or IV melanoma that can be surgically removed. Notes: * In-transit melanoma is acceptable. * Patients can enroll regardless of their BRAF mutational status * 1cm of tumor needs to be visible on standard imaging (i.e. FDG PET or CT scan) * Screening laboratory values must meet the following criteria: * WBC ≥ 2.0x109/L * Neutrophils ≥ 1.5x109/L * Platelets ≥ 100 x109/L * Hemoglobin ≥ 5.5 mmol/L * Creatinine ≤ 1.5x ULN * AST ≤ 1.5 x ULN and ALT ≤ 1.5 x ULN * Bilirubin ≤1.5 X ULN * Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of study treatment (ipilimumab/nivolumab) * Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of ipilimumab + nivolumab * Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of study treatment (ipilimumab/nivolumab) Note: Women who are not of childbearing potential (i.e., who are postmenopausal), or surgically sterile as well as azoospermic men do not require contraception
Exclusion criteria
* Subjects with any active autoimmune disease (current symptoms or requirement for immunosuppression at the time of study start). * Positive active hepatitis B viral infection (+viral load by PCR) * Prior immunotherapy targeting CTLA-4 and/or PD-1/PD-L1 for any disease. * Potentially unresectable melanoma. * History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) * History of severe hypersensitivity reaction to any monoclonal antibody * Underlying medical conditions that, in the Investigator's opinion, will make the administration of treatment hazardous or obscure the interpretation of toxicity * Patients who have undergone splenectomy or have other splenic disorders. The normal spleen usually has CD8+ cell activity and serves as a positive control to enable proper imaging technique. * Use of other investigational drugs before study drug administration 30 days and 5 half-times before study inclusion * Pregnant or nursing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major pathologic responses/MPR | up to 2 years | Participants' disease will be assessed for MPR as per previously established criteria for neoadjuvant trials (near complete response ≤10% viable; complete response 0% viable). Pathologic response (≤50% viable) will also be estimated. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMichael Postow, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed